vs
Side-by-side financial comparison of LivaNova PLC (LIVN) and TENNANT CO (TNC). Click either name above to swap in a different company.
LivaNova PLC is the larger business by last-quarter revenue ($360.9M vs $291.6M, roughly 1.2× TENNANT CO). LivaNova PLC runs the higher net margin — 8.6% vs -1.5%, a 10.1% gap on every dollar of revenue. On growth, LivaNova PLC posted the faster year-over-year revenue change (12.1% vs -11.3%). LivaNova PLC produced more free cash flow last quarter ($50.2M vs $9.7M). Over the past eight quarters, LivaNova PLC's revenue compounded faster (10.6% CAGR vs -3.2%).
LivaNova, plc is an American medical device manufacturer based in the UK. The company develops devices used for cardiac surgery and neuromodulation. The company was formed in 2015 by a $2.7B merger between Houston, Texas-based Cyberonics, Inc. and Milan, Italy-based Sorin S.p.a. The company trades on the NASDAQ stock exchange under the ticker symbol "LIVN".
The Tennant Company (TNC:NYQ) is a company with about 4000 employees that provides cleaning products. It is a company that is listed in the New York Stock Exchange.
LIVN vs TNC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $360.9M | $291.6M |
| Net Profit | $30.9M | $-4.4M |
| Gross Margin | 65.2% | 34.6% |
| Operating Margin | 11.8% | -1.4% |
| Net Margin | 8.6% | -1.5% |
| Revenue YoY | 12.1% | -11.3% |
| Net Profit YoY | -44.7% | -166.7% |
| EPS (diluted) | $0.57 | $-0.21 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $360.9M | $291.6M | ||
| Q3 25 | $357.8M | $303.3M | ||
| Q2 25 | $352.5M | $318.6M | ||
| Q1 25 | $316.9M | $290.0M | ||
| Q4 24 | $321.8M | $328.9M | ||
| Q3 24 | $318.1M | $315.8M | ||
| Q2 24 | $318.6M | $331.0M | ||
| Q1 24 | $294.9M | $311.0M |
| Q4 25 | $30.9M | $-4.4M | ||
| Q3 25 | $26.8M | $14.9M | ||
| Q2 25 | $27.2M | $20.2M | ||
| Q1 25 | $-327.3M | $13.1M | ||
| Q4 24 | $55.9M | $6.6M | ||
| Q3 24 | $33.0M | $20.8M | ||
| Q2 24 | $16.3M | $27.9M | ||
| Q1 24 | $-41.9M | $28.4M |
| Q4 25 | 65.2% | 34.6% | ||
| Q3 25 | 68.4% | 42.7% | ||
| Q2 25 | 67.8% | 42.1% | ||
| Q1 25 | 69.7% | 41.4% | ||
| Q4 24 | 68.2% | 41.3% | ||
| Q3 24 | 70.8% | 42.4% | ||
| Q2 24 | 68.7% | 43.1% | ||
| Q1 24 | 70.3% | 44.2% |
| Q4 25 | 11.8% | -1.4% | ||
| Q3 25 | 15.1% | 7.4% | ||
| Q2 25 | 15.4% | 9.6% | ||
| Q1 25 | 15.3% | 6.8% | ||
| Q4 24 | 11.5% | 2.3% | ||
| Q3 24 | 11.2% | 9.7% | ||
| Q2 24 | 12.6% | 11.7% | ||
| Q1 24 | 5.5% | 12.1% |
| Q4 25 | 8.6% | -1.5% | ||
| Q3 25 | 7.5% | 4.9% | ||
| Q2 25 | 7.7% | 6.3% | ||
| Q1 25 | -103.3% | 4.5% | ||
| Q4 24 | 17.4% | 2.0% | ||
| Q3 24 | 10.4% | 6.6% | ||
| Q2 24 | 5.1% | 8.4% | ||
| Q1 24 | -14.2% | 9.1% |
| Q4 25 | $0.57 | $-0.21 | ||
| Q3 25 | $0.49 | $0.80 | ||
| Q2 25 | $0.50 | $1.08 | ||
| Q1 25 | $-6.01 | $0.69 | ||
| Q4 24 | $1.04 | $0.35 | ||
| Q3 24 | $0.60 | $1.09 | ||
| Q2 24 | $0.30 | $1.45 | ||
| Q1 24 | $-0.78 | $1.49 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $635.6M | — |
| Total DebtLower is stronger | $376.1M | $273.2M |
| Stockholders' EquityBook value | $1.2B | $601.6M |
| Total Assets | $2.6B | $1.3B |
| Debt / EquityLower = less leverage | 0.31× | 0.45× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $635.6M | — | ||
| Q3 25 | $646.1M | — | ||
| Q2 25 | $593.6M | — | ||
| Q1 25 | $738.4M | — | ||
| Q4 24 | $428.9M | — | ||
| Q3 24 | $346.4M | — | ||
| Q2 24 | $329.2M | — | ||
| Q1 24 | $309.2M | — |
| Q4 25 | $376.1M | $273.2M | ||
| Q3 25 | $434.5M | $238.3M | ||
| Q2 25 | $430.6M | $213.4M | ||
| Q1 25 | $628.2M | $213.3M | ||
| Q4 24 | $627.0M | $198.2M | ||
| Q3 24 | $625.5M | $208.6M | ||
| Q2 24 | $624.5M | $205.6M | ||
| Q1 24 | $623.8M | $207.4M |
| Q4 25 | $1.2B | $601.6M | ||
| Q3 25 | $1.2B | $640.9M | ||
| Q2 25 | $1.1B | $651.9M | ||
| Q1 25 | $1.0B | $624.4M | ||
| Q4 24 | $1.3B | $620.8M | ||
| Q3 24 | $1.3B | $647.2M | ||
| Q2 24 | $1.2B | $624.6M | ||
| Q1 24 | $1.2B | $614.6M |
| Q4 25 | $2.6B | $1.3B | ||
| Q3 25 | $2.6B | $1.3B | ||
| Q2 25 | $2.5B | $1.2B | ||
| Q1 25 | $2.6B | $1.2B | ||
| Q4 24 | $2.5B | $1.2B | ||
| Q3 24 | $2.5B | $1.2B | ||
| Q2 24 | $2.5B | $1.2B | ||
| Q1 24 | $2.5B | $1.2B |
| Q4 25 | 0.31× | 0.45× | ||
| Q3 25 | 0.38× | 0.37× | ||
| Q2 25 | 0.38× | 0.33× | ||
| Q1 25 | 0.61× | 0.34× | ||
| Q4 24 | 0.47× | 0.32× | ||
| Q3 24 | 0.48× | 0.32× | ||
| Q2 24 | 0.50× | 0.33× | ||
| Q1 24 | 0.51× | 0.34× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $82.4M | $14.2M |
| Free Cash FlowOCF − Capex | $50.2M | $9.7M |
| FCF MarginFCF / Revenue | 13.9% | 3.3% |
| Capex IntensityCapex / Revenue | 8.9% | 1.5% |
| Cash ConversionOCF / Net Profit | 2.67× | — |
| TTM Free Cash FlowTrailing 4 quarters | $173.3M | $43.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $82.4M | $14.2M | ||
| Q3 25 | $85.1M | $28.7M | ||
| Q2 25 | $62.9M | $22.5M | ||
| Q1 25 | $24.0M | $-400.0K | ||
| Q4 24 | $78.7M | $37.5M | ||
| Q3 24 | $51.0M | $30.7M | ||
| Q2 24 | $43.4M | $18.6M | ||
| Q1 24 | $10.0M | $2.9M |
| Q4 25 | $50.2M | $9.7M | ||
| Q3 25 | $62.2M | $22.3M | ||
| Q2 25 | $47.8M | $18.7M | ||
| Q1 25 | $13.2M | $-7.4M | ||
| Q4 24 | $68.3M | $28.1M | ||
| Q3 24 | $32.8M | $26.4M | ||
| Q2 24 | $31.2M | $14.4M | ||
| Q1 24 | $3.6M | $-100.0K |
| Q4 25 | 13.9% | 3.3% | ||
| Q3 25 | 17.4% | 7.4% | ||
| Q2 25 | 13.6% | 5.9% | ||
| Q1 25 | 4.2% | -2.6% | ||
| Q4 24 | 21.2% | 8.5% | ||
| Q3 24 | 10.3% | 8.4% | ||
| Q2 24 | 9.8% | 4.4% | ||
| Q1 24 | 1.2% | -0.0% |
| Q4 25 | 8.9% | 1.5% | ||
| Q3 25 | 6.4% | 2.1% | ||
| Q2 25 | 4.3% | 1.2% | ||
| Q1 25 | 3.4% | 2.4% | ||
| Q4 24 | 3.2% | 2.9% | ||
| Q3 24 | 5.7% | 1.4% | ||
| Q2 24 | 3.8% | 1.3% | ||
| Q1 24 | 2.2% | 1.0% |
| Q4 25 | 2.67× | — | ||
| Q3 25 | 3.18× | 1.93× | ||
| Q2 25 | 2.32× | 1.11× | ||
| Q1 25 | — | -0.03× | ||
| Q4 24 | 1.41× | 5.68× | ||
| Q3 24 | 1.55× | 1.48× | ||
| Q2 24 | 2.65× | 0.67× | ||
| Q1 24 | — | 0.10× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LIVN
| Other | $169.4M | 47% |
| Neuromodulation Segment | $119.7M | 33% |
| Cardiopulmonary Segment | $71.8M | 20% |
TNC
| Equipment Sales | $165.5M | 57% |
| Parts And Consumables | $69.1M | 24% |
| Service And Other | $57.0M | 20% |
